The Cocktail Report (sound really smart around your friends):
BioAge Labs announced Phase 1 results for BGE-102, an oral once-daily pill that inhibits the NLRP3 inflammasome (a sensor protein inside immune cells that acts as the body's internal "smoke detector" for cellular stress, and one of the central drivers of aging-related chronic inflammation).
Participants with obesity and elevated inflammation taking 60 mg daily for three weeks saw their high-sensitivity C-reactive protein (hsCRP, the standard blood marker of body-wide inflammation) drop by a median of 86%. The 120 mg dose produced nearly identical results.
No serious adverse events occurred, no patients dropped out early, and side effects were mild, clearing a critical safety bar for a drug intended for long-term use.
The NLRP3 inflammasome is activated by the same cellular debris that accumulates with age: cholesterol crystals, amyloid plaques, damaged mitochondrial fragments, and secretory products from senescent (zombie) cells. It likely does not just respond to aging but actively drives it.
BioAge discovered BGE-102 by working backward: they analyzed biobank samples from 100,000+ people followed over decades, identified molecular features that predicted who aged well, and the NLRP3 pathway emerged as one of the strongest signals.
A landmark 2017 Stanford study found that people over 85 with high inflammasome gene expression had worse cardiovascular health and higher all-cause mortality than peers with low inflammasome expression.
BGE-102 is designed to penetrate the brain, which matters because the same NLRP3 pathway in brain immune cells is linked to Alzheimer's: APOE4 carriers (roughly 25% of people of European ancestry) may be especially vulnerable to this inflammasome-driven mechanism.
Next steps: a Phase 2 cardiovascular risk trial is planned, plus a Phase 1b/2a trial in diabetic macular edema starting mid-2026.
Your personal hsCRP number (from any standard blood panel) tells you your baseline: below 1 mg/L is low risk, 1 to 3 mg/L is average, above 3 mg/L is elevated, and above 10 mg/L warrants follow-up.
BGE-102 is not yet approved or available; it is moving into Phase 2 trials now.
Your blood contains a number most doctors do not explain: hsCRP, or high-sensitivity C-reactive protein, a reliable marker of chronic inflammation. A new drug just moved one step closer to resetting it.
BioAge Labs announced Phase 1 results for BGE-102, an oral daily pill targeting the NLRP3 inflammasome. In adults with obesity and elevated inflammation, three weeks of once-daily dosing dropped median hsCRP levels by 86%, with a safety profile comparable to placebo.
The NLRP3 inflammasome (a molecular sensor inside immune cells that detects internal cellular stress) evolved to amplify the immune response to genuine threats. In aging bodies, however, it detects a relentless stream of internally generated signals: oxidized lipids, amyloid fragments, damaged mitochondrial DNA, and secretory products from senescent cells.
It fires chronically against threats it cannot clear, producing the persistent low-grade inflammation researchers call inflammaging.
BioAge found BGE-102 by going upstream of the disease: rather than starting with a condition and searching for a drug target, they analyzed samples from more than 100,000 people in the HUNT biobank in Norway, followed for decades with mortality outcomes attached. The NLRP3 pathway was among the strongest molecular signals separating people who aged well from those who developed chronic disease.
The Alzheimer's connection is particularly significant. The NLRP3 inflammasome operates inside microglia (the brain's resident immune cells), where amyloid plaques activate it, and its inflammatory signals promote further amyloid accumulation in a self-reinforcing loop.
BioAge designed BGE-102 to cross the blood-brain barrier for exactly this reason, and for APOE4 carriers (roughly 25% of people of European ancestry and three to twelve times the baseline Alzheimer's risk), evidence suggests a substantial portion of that excess risk flows through this pathway.
If you have had an hsCRP test (available through most standard blood panels), the number is directly relevant. The American Heart Association considers below 1 mg/L low risk, 1 to 3 mg/L average, and above 3 mg/L elevated cardiovascular risk.
The clinical trials targeting this pathway, including the large ongoing ZEUS trial testing whether reducing IL-6 prevents heart attacks, enroll people with hsCRP above 2 mg/L.
Why Should You Care?
BGE-102 is not a treatment for one disease. It targets the underlying inflammatory mechanism that connects heart disease, Alzheimer's, metabolic dysfunction, and accelerated aging at the molecular level.
An 86% median drop in the primary marker of that mechanism in three weeks, with no serious side effects, is one of the most compelling Phase 1 results in the longevity drug pipeline this year. Phase 2 results will tell us whether that biomarker change translates into real clinical outcomes.
Citations:
Glorioso C, MD, PhD. "BioAge's Longevity Drug Cleared Phase 1 with an 86% Drop in Inflammation." NeuroAge / Substack. May 1, 2026. https://open.substack.com/pub/drglorioso/p/bioages-longevity-drug-cleared-phase
BioAge Labs. BGE-102 program overview. https://www.bioagelabs.com
Furman D, et al. "Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states." Nature Medicine. 2017. https://pubmed.ncbi.nlm.nih.gov/28650481/
Heneka MT, et al. "NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice." Nature. 2013. https://pubmed.ncbi.nlm.nih.gov/23392667/
